[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimers-disease-incl-subtypes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimers-disease-incl-subtypes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100488671","enhancing-shared-decision-making-to-guide-care-for-people-with-dementia-and-diabetes-100488671",false,"NCT05643144","Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes","Enhancing Shared Decision-making to Prompt and Guide Individualized Care for People With Alzheimer's Disease and Diabetes","Patient-Caregiver Dyad Inclusion Criteria (Aims 1 + 2):\n\n* patient must have dual diagnosis of MCI or ADRD and diabetes (DM)\n* patient must have active prescriptions for DM\n* patient must have had at least one visit to an Eskenazi or IU Health primary care clinic within 12 months\n* patient must be able to provide assent and have a legally authorized representative (LAR) consent on their behalf if patient lacks capacity to consent\n* patient must have a caregiver aged 18 years or older who interacts daily, or almost daily, with the patient\n* patient and caregiver must both speak English\n* patient and caregiver must both reside in the community\n* dyad must have internet access\n\nPatient-Caregiver Dyad Exclusion Criteria (Aims 1 +2):\n\n* patient has terminal illness\n* use of an automated insulin delivery system\n* patient is receiving dialysis\n* patient is taking ascorbic acid during monitoring period\n* patient has existing implanted medical devices\n* patient has a bleeding disorder\n* patient has a pre-existing arm skin lesions\n* patient has an allergy to medical adhesive or isopropyl alcohol\n* patient has plans for imaging or diathermy treatment during the study period\n\nClinician Participant Inclusion Criteria (Aim 2):\n\n* primary care physicians\n* nurses\n* pharmacists\n* nutritionists\n* psychologists\n* medical residents\n\nClinician Participant Exclusion Criteria (Aim 2):\n\n* only treats patients younger than 65 years\n* does not manage patients' DM","ALL","65 Years",{"count":19,"type":20},62,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to test CGM ASSIST. This is a digital tool that uses an interactive information display-an easy-to-read screen designed to help people with dementia (or memory loss) and diabetes, as well as their caregivers and doctors.\n\nManaging diabetes is often difficult for people with memory issues. This study uses a Continuous Glucose Monitor (CGM), which is a device that tracks blood sugar levels in real-time. CGM ASSIST adds a new way to see this data through interactive displays. These displays show clear information and medical guidelines to help patients and caregivers make sense of the glucose readings.\n\nThe study aims to:\n\n* Increase Awareness: Help patients and caregivers recognize the dangers of low blood sugar (hypoglycemia) and how to treat it.\n* Improve Teamwork: Encourage \"shared decision-making,\" where patients, caregivers, and doctors work together to make health choices.\n* Test Feasibility: See if it is easy and helpful for people with memory loss to use these interactive displays in their daily lives.\n* Understand Experiences: Learn how the thoughts and feelings of patients and families affect how they manage diabetes.\n\nBy using these interactive displays, the researchers hope to make it easier for families to understand their health needs and communicate better with their medical team.\n\nParticipants will:\n\n* Answer a survey about how they manage their diabetes\n* Learn how to use a Continuous Glucose Monitor and wear it for 14 days\n* Answer 3 brief telephone surveys during these 14 days\n* Complete a clinic visit with their doctor and answer a final survey on how this visit went using the CGM ASSIST report",[26,27,28,29],"Diabetes","Alzheimer's Disease (Incl Subtypes)","Dementia","Hypoglycemia",[31,32,33,34],"Continuous glucose monitoring","Shared decision-making","Human factors","Primary care","RECRUITING","2026-05-05",{"date":38,"type":39},"2026-05-07","ACTUAL",{"date":41,"type":20},"2026-07-10",{"date":43,"type":20},"2027-06-30",{"name":45,"class":46},"Indiana University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100559518","improving-pcp-advance-care-planning-for-people-with-adrd-100559518","NCT06565169","Improving PCP Advance Care Planning for People With ADRD","Improving Primary Care Clinician's Advance Care Planning Alzheimer's Disease and Related Dementias","AD-ACP","Inclusion Criteria:\n\nPrimary care team member (PCTM) eligibility:\n\n* Must be an MD\u002FAPP, employed at a primary care clinic within UNC HEALTH clinics with ≥60 PLwD encounters per year, who sees older adult patients, along with their associated nurses and social workers.\n* Eligibility for training with AD ACP Toolkit will include the above and the provision of care at an intervention clinic.\n* For Aim 3, only the trained intervention site primary care team members will be eligible for the implementation surveys or the interviews.\n\nPLwD eligibility:\n\n* Must be a PLwD age 65 years or older seen by either the intervention or control sites' primary care teams' MD\u002FAPP in the 18-month intervention window for Aim 1.\n* PLwD will be eligible only after we confirm the presence of the AD\u002FADRD diagnosis.\n* All PLwD with a ≥50% 5-year all-cause mortality risk seen by the PCTM MD\u002FAPP over the 18-month intervention period will be eligible for the healthcare utilization analyses in Aim 2.\n\nExclusion Criteria:\n\nPrimary care team member exclusion criteria:\n\n* We will exclude primary care team members who do not care for older adults (e.g. pediatricians or lactation nurses), are employed at geriatric specialty or dementia specialty clinics, or are without a primary care panel (e.g., only urgent care).\n\nPLwD exclusion criteria:\n\n* Patients will be excluded if they have not been seen in the past 18 months by their primary care team, or if they do not have a diagnosis of ADRD.","18 Years","99 Years",{"count":59,"type":20},120,[23],"This study will test the Dementia Advance Care Planning (AD ACP) Toolkit intervention to usual care in facilitating goals of care (GOC) discussions between People Living with Dementia (PLwD) and primary care team members over an 18-month period. The primary outcome is to assess the frequency and quality of GOC discussions with PLwD. Secondary outcomes include the identification of preferred surrogates, assessment of decisional capacity, and the completion of portable ACP orders. This randomized clinical trial aims to determine if the AD ACP Toolkit can enhance ACP practices and improve care planning outcomes for PLwD compared to the standard care approach.",[63,28,27,64],"Alzheimer Disease","Aging",[66,67,68,69],"Advance Care Planning","Primary Care","Goals of Care","Communication","2026-04-09",{"date":72,"type":39},"2026-04-14",{"date":74,"type":39},"2025-03-19",{"date":76,"type":20},"2028-05-31",{"name":78,"class":46},"University of Pittsburgh",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":47},"100489597","chronic-treatment-of-alzheimers-disease-by-gamma-light-and-sound-therapy-100489597","NCT05655195","Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy","Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation","Inclusion Criteria:\n\nSubjects may be enrolled into the study if they meet all of the following criteria:\n\n* Subject is between the ages of 65 - 100.\n* Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.\n* Subject is willing to sign informed consent document.\n* If subject is deemed to not have capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n* Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.\n\nExclusion Criteria:\n\nSubjects who meet any of the following conditions will not be enrolled in the study:\n\n* Subjects who do not have healthcare.\n* Subjects who are currently taking amyloid reducing therapy.\n* Subjects who have \\> 4 cerebral microbleeds or 1 macrobleed in their brain\n* Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).\n* Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments\n* Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).\n* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.\n* Subjects with history of seizure or epilepsy\n* Subjects with clinically significant suicide risk and\u002For suicide attempt in the past 1 year.\n* Subjects with behavioral problems such as aggression\u002Fagitation\u002Fimpulsivity that might interfere with their ability to comply with protocol.\n* Subjects with untreated or unstable depression\n* Active treatment with one or more anti-epileptic agent.\n* Subjects who have had a stroke within the past 24 months.\n* Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)\n* Subjects diagnosed with migraine headache.\n* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and\u002For sacral nerve stimulator.\n* Subjects who have profound hearing or visual impairment.\n* Subjects who have a life expectancy of less than 2 years.\n* Subjects who are pregnant.\n* Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.",true,"100 Years",{"count":89,"type":20},60,[23],"Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the present study, 60 participants with mild Alzheimer's disease will be enrolled and will use this light and sound device at-home daily for 6-months. Investigators will measure changes in brain waves with EEG, blood biomarkers, the microbiome via fecal samples, functional and structural MRI scans, memory and cognitive testing, and questionnaires at 3 in-person visits throughout the study. After the 6-month time point, participants will have the option of continuing in the study for at least one year and completing yearly study visits. This study will provide critical insight into extended therapy involving non-invasive 40Hz sensory stimulation as a possible therapeutic strategy for mild to moderate Alzheimer's disease.",[63,93,94,27,95,96],"Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Alzheimer's","Alzheimer's Disease",[95,98,99,100,101],"Alzheimer","Alzheimer's disease","Light and Sound Stimulation","Tactile Stimulation","2026-03-24",{"date":104,"type":39},"2026-03-30",{"date":106,"type":39},"2022-12-14",{"date":108,"type":20},"2026-09-01",{"name":110,"class":46},"Massachusetts Institute of Technology"]